olaparib
astrazeneca,merck
['vance', 'solo1', 'olaparib', 'brca', 'ovarian']
#esmo2022 solo1 trial: olaparib achieved long-term remission in women with newly diagnosed advanced ovarian cancer and brcam. outstanding data - 67.0% of olaparib patients were alive at 7 years. 
MD, PhD Breast and Gynecologic Cancer Unit. Medical Oncology Division